Hubbry Logo
Trichomonas vaginalisTrichomonas vaginalisMain
Open search
Trichomonas vaginalis
Community hub
Trichomonas vaginalis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Trichomonas vaginalis
Trichomonas vaginalis
Trichomonas vaginalis
View on Wikipedia
from Wikipedia

Trichomonas vaginalis
Trichomonas vaginalis observed by scanning electron microscopy
Trichomonas vaginalis observed by scanning electron microscopy showing the axostyle (ax), the anterior flagella (af) and the undulating membrane (rf).[1]
Scientific classification Edit this classification
Domain: Eukaryota
Phylum: Metamonada
Order: Trichomonadida
Family: Trichomonadidae
Genus: Trichomonas
Species:
T. vaginalis
Binomial name
Trichomonas vaginalis
(Donné 1836)

Trichomonas vaginalis is an anaerobic, flagellated protozoan parasite and the causative agent of a sexually transmitted disease called trichomoniasis. It is the most common pathogenic protozoan that infects humans in industrialized countries.[2] Infection rates in men and women are similar but women are usually symptomatic, while infections in men are usually asymptomatic. Transmission usually occurs via direct, skin-to-skin contact with an infected individual, most often through vaginal intercourse. It is estimated that 160 million cases of infection are acquired annually worldwide.[3] The estimates for North America alone are between 5 and 8 million new infections each year, with an estimated rate of asymptomatic cases as high as 50%.[4] Usually treatment consists of either metronidazole or tinidazole.[5] More recent studies on Trichomonas vaginalis have shed light on the parasite's evolution, genomic complexity, and pathogenesis processes.[6] New population studies and genomic sequences illustrate the genetic variability of the parasite and the parasite's possible resistance to treatment. Understanding of host-pathogen interaction and prevention strategies remains a driving force behind public health.

Clinical

[edit]
Trichomonas vaginalis protozoa. Colorized SEM
The structure of Trichomonas vaginalis
Main article: Trichomoniasis

History

[edit]
Trichomonas vaginalis from a vaginal swab. This is a heavy infection; there were probably thousands of trichomonads in the vagina.

Alfred Francois Donné (1801–1878) was the first to describe a procedure to diagnose trichomoniasis through "the microscopic observation of motile protozoa in vaginal or cervical secretions" in 1836. He published this in the article entitled, "Animalcules observés dans les matières purulentes et le produit des sécrétions des organes génitaux de l'homme et de la femme" in the journal, Comptes rendus de l'Académie des sciences.[7] With it, he created the binomial name of the parasite as Trichomonas vaginalis.[8] 80 years after the initial discovery of the parasitic protozoan, Hohne declared Trichomoniasis as a clinical entity in 1916.[9]

Signs and symptoms

[edit]
Pap smear, showing infection by Trichomonas vaginalis. Papanicolaou stain, 400×

Most women (85%) and men (77%) infected with T. vaginalis do not have symptoms. Half of these women can develop symptoms within 6 months and can have vaginal erythema, dyspareunia, dysuria, and vaginal discharge, which is often diffuse, malodorous, and yellow-green, along with itching in the genital region. "Strawberry cervix," occurs in about 5% of women. In men, it can cause urethritis, epididymitis and prostatitis.[10]

Complications

[edit]

Some of the complications of Trichomonas vaginalis in women include: preterm delivery, low birth weight, and increased mortality as well as predisposing to human immunodeficiency virus infection, AIDS, and cervical cancer.[11] Trichomonas vaginalis can be seen in diverse locations within the body, such as," in the urinary tract, fallopian tubes, and pelvis and can cause pneumonia, bronchitis, and oral lesions."[12]

Diagnosis

[edit]
A single trichomonas by phase contrast microscopy
Trichomonas vaginalis Gram stain (arrows)

Classically, with a cervical smear, infected women may have a transparent "halo" around their superficial cell nucleus but more typically the organism itself is seen with a, "slight cyanophilic tinge, faint eccentric nuclei, and fine acidophilic granules."[13] It is unreliably detected by studying a genital discharge or with a cervical smear because of their low sensitivity. Trichomonas vaginalis is also routinely diagnosed via a wet mount, in which motility is observed. Currently, the most common method of diagnosis is via overnight culture,[14][15] with a sensitivity range of 75–95%.[16] Newer methods, such as rapid antigen testing and transcription-mediated amplification, have even greater sensitivity, but are not in widespread use.[16]

Prevention and Treatment

[edit]

Infection is treated and cured with metronidazole[17] or tinidazole. The CDC recommends a one time dose of 2 grams of either metronidazole or tinidazole as the first-line treatment; the alternative treatment recommended is 500 milligrams of metronidazole, twice daily, for seven days if there is failure of the single-dose regimen.[18] Medication should be prescribed to any sexual partner(s) as well because they may be asymptomatic carriers.[19]Trichomoniasis due to T. vaginalis ranks as the most prevalent non-viral sexually transmitted disease, and there were about 156 million new cases in 2020[6] reported worldwide. It is a curable infection that occurs through unprotected intercourse. Measures for prevention include the use of a condom consistently and screening in sexually active participants. Symptoms include urethral or vaginal irritation, unusual discharge, itching in the genitals, frequent urination, and dysuria. Antigen detection and the use of nucleic acid amplification tests are able to be used in diagnosis. A single dose of oral metronidazole or tinidazole and other regimens for resistant strains are the recommended treatments. Despite the relatively low rate of resistance, it remains a rising public concern. There is no vaccine for trichomoniasis and the prevention and early treatment of the disease are hence vital.

Pathogenesis

[edit]

T. vaginalis causes a very common sexually transmitted disease by adhering[20] to vaginal epithelial cells and breaking them down. It secretes extracellular vesicles that disrupt immune function and increase adhesion. Some strains have intracellular viruses or bacteria within them that worsen infections. The parasite is associated with disruptions to vaginal microflora. Neutrophils are the primary immune cell associated with infection, which can kill the parasite through trogocytosis.

Morphology

[edit]
Trichomonas vaginalis May-Grünwald-Giemsa staining. The spike-like axostyle can be seen on the left.

Trichomonas vaginalis exists in only one morphological stage, a trophozoite, and cannot encyst (or form cysts.) This protozoan does not typically adhere to one shape, as in different conditions, the parasite has the ability to change. When in culture separate from the host, it usually displays a more "pear" or oval shaped morphology, but when present in a living host, specifically on the epithelial cells of the vaginal wall, the shape is more "amoeboid".[21] It is slightly larger than a white blood cell, measuring 9 × 7 μm. In both forms, Trichomonas vaginalis has five flagella – four protruding from the front or anterior of the parasite and the fifth on the back or posterior end. The functionality of the fifth flagellum is not known.[22] In addition, a barb-like axostyle projects opposite the four-flagella bundle. All of these flagella are connected to an "undulating" membrane.[22] The axostyle may be used for attachment to surfaces and may also cause the tissue damage seen in trichomoniasis.[23] The nucleus is usually elongated, and is located near the anterior end of the protozoan within the cytoplasm which contains many hydrogenosomes (closed-membrane organelle with the ability to produce both adenosine triphosphate and hydrogen while in anaerobic conditions.)[24]

While Trichomonas vaginalis does not have a cyst form, the organism can survive for up to 24 hours in urine, semen, or even water samples. A nonmotile, round, pseudocystic form with internalized flagella has been observed under unfavorable conditions.[25] This form is generally regarded as a degenerate stage as opposed to a resistant form,[25] although viability of pseudocystic cells has been occasionally reported.[26] The ability to revert to trophozoite form, to reproduce and sustain infection has been described,[27] along with a microscopic cell staining technique to visually discern this elusive form.[28]

Metabolism

[edit]
Trichomonas vaginalis from a human vagina x 400

Trichomonas vaginalis is an anaerobe.[29] There is an absence of cytochrome C and mitochondria, thus making oxygen uptake and synthesis of adenosine triphosphate via oxidative phosphorylation difficult.[29] Although it contains no mitochondria, an analogous structure called a hydrogenosome, which is the site of fermentative oxidation of pyruvate, carries out many of the same metabolic processes. Carbohydrates, specifically those with alpha1,4- glycosidic linkages, are metabolized and eventually fermented to produce products such as acetate, lactate, malate, glycerol and CO2 under aerobic conditions. Hydrogen is produced under anaerobic conditions.[30] Outside the hydrogenosome, carbohydrate metabolism also occurs freely in the cytoplasm. The Embden-Meyerhof-Parnas pathway[30] is used to convert glucose into phosphoenolpyruvate which ultimately becomes pyruvate.

Virulence factors

[edit]

Although Trichomonas vaginalis exists as a trophozoite in its infective form, its amoeboid form is also an important characteristic that adds to how well it is able to infect its host. The amoeboid form, which is pancake shaped, allows for greater surface area contact with epithelial cells of the vagina, cervix, urethra, and prostate.[31] The pseudocyst form is also a way in which the microbe can infect more efficiently, but this only induced when exposed to cold and other stressors.[31] These various forms are accompanied with differing protein phosphorylation profiles which are triggered by environmental pressures.[31]

One of the hallmark features of Trichomonas vaginalis is the adherence factors that allow cervicovaginal epithelium colonization in women. The adherence that this organism illustrates is specific to vaginal epithelial cells being pH, time, and temperature dependent.[32] A variety of virulence factors mediate this process some of which are the microtubules, microfilaments, bacterial adhesins (4), and cysteine proteinases. The adhesins are four trichomonad enzymes called AP65, AP51, AP33, and AP23 that mediate the interaction of the parasite to the receptor molecules on vaginal epithelial cells.[33] The best characterized surface molecule associated with one of the four adhesins is called Trichomonas vaginalis lipoglycans.[31] This molecule is the most abundant on the surface of Trichomonas vaginalis, aids in sticking to vaginal epithelial cells, and can also influence how the human immune system responds, affecting inflammatory responses and macrophages in the body.[31] Cysteine proteinases may be another virulence factor because not only do these 30 kDa proteins bind to host cell surfaces but also may degrade extracellular matrix proteins like hemoglobin, fibronectin or collagen IV.[32]

Genome sequencing and statistics

[edit]

The Trichomonas vaginalis genome is approximately 160 megabases in size[34] – ten times larger than predicted from earlier gel-based chromosome sizing.[35] (The human genome is ~3.5 gigabases by comparison.[36]) As much as two-thirds of the Trichomonas vaginalis sequence consists of repetitive and transposable elements, indicative of a recent drastic, evolutionarily expansion of the genome. The total number of predicted protein-coding genes is ~60,000, with the genome being around 65% repetitive (virus-like, transposon-like, retrotransposon-like, and unclassified repeats, all with high copy number and low polymorphism).[37] Approximately 26,000 of the protein-coding genes have been classed as 'evidence-supported' (similar either to known proteins, or to expressed sequence tags), while the remainder have no known function.[37]These extraordinary genome statistics are likely to change downward as the genome sequence, currently very fragmented due to the difficulty of ordering repetitive DNA, is assembled into chromosomes, and as more transcription data (expressed sequence tags, microarrays) accumulate.[37]

TrichDB.org was launched as a free, public genomic data repository and retrieval service devoted to genome-scale trichomonad data. The site currently contains all of the Trichomonas vaginalis sequence project data, several expressed sequence tag libraries, and tools for data mining and display.[38] TrichDB is part of the EupathDB functional genomics database project funded by the National Institutes of Health and National Institute of Allergy and Infectious Diseases.[38]

Genetic diversity

[edit]

A 2023 study[39] conducted using next-generation multilocus sequence typing found high genetic variation in T. vaginalis isolates of geographically disparate populations in Australia and Ghana. Among 178 clinical isolates, scientists found 36 alleles and 48 distinct sequence types, of which nearly half were not previously recorded. In spite of the variation, there was high linkage disequilibrium showing that the population was predominantly clonal and subjected to very little recombination. Because there was a third genetic group that was unassigned implies that there might have been historical recombination events that have structured the population in the way that it currently exists. These findings highlight the need for more studies to establish how genetic variability affects pathogenicity as well as the efficacy of treatment.

Increased susceptibility to human immunodeficiency virus

[edit]

In addition to inflammation that Trichomonas vaginalis causes, the parasite also causes lysis of epithelial cells and red blood cells in the area leading to more inflammation and disruption of the protective barrier usually provided by the epithelium. Having Trichomonas vaginalis also may increase the chances of the infected woman transmitting human immunodeficiency virus to her sexual partner(s).[40][41]

Evolution

[edit]

The biology of Trichomonas vaginalis has implications for understanding the origin of sexual reproduction in eukaryotes. Trichomonas vaginalis is not known to undergo meiosis, a key stage of the eukaryotic sexual cycle. However, when Malik et al.[42] examined Trichomonas vaginalis for the presence of 29 genes known to function in meiosis, they found 27 homologous genes to the ones found in animals, fungi, plants and other protists, including eight of nine genes that are specific to meiosis in model organisms.[42] These findings suggest that Trichomonas vaginalis has the capability for meiotic recombination, and hence "parasexual" reproduction.[42] 21 of the 27 meiosis genes were also found in another parasite Giardia lamblia (also called Giardia intestinalis), indicating that these meiotic genes were present in a common ancestor of Trichomonas vaginalis and G. intestinalis.[42] Since these two species are descendants of lineages that are highly divergent among eukaryotes, these meiotic genes were likely present in a common ancestor of all eukaryotes.[42] T. vaginalis's evolution also manifests in an unusually huge and complicated genome that comprises about 160 megabases and about 60,000 genes. The genome comprises repetitive and noncoding sequences[43] which signify a gene duplication and possible gene loss history. T. vaginalis does not appear to undergo traditional meiosis despite the fact that there are genes related to meiosis. The reproductive process in this organism seems to result in genetic variability that has a bearing on adaptability as well as drug resistance.

Global prevalence and infection risk factors

[edit]

A systematic review and meta-analysis based on 425 articles, published in 2025, outlined the following results [44]. The global prevalence rate of T. vaginalis is 8%, with country-specific rates ranging from 1% to 35%. The prevalence was correlated with behavior and was significantly higher in subgroups including smoking, drug use, and not using condoms, and in the group with other sexually transmitted infections, including HIV, HSV, and Chlamydia infection. Socioeconomic factors such as being unmarried, having a low income, and unstable employment were associated with an increased risk.[44]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Trichomonas vaginalis

View on Grokipedia
from Grokipedia
Trichomonas vaginalis is a motile, flagellated protozoan parasite that causes , the most common non-viral (STI) worldwide, affecting the urogenital tract of humans. The parasite exists solely in the form, lacking a stage, and measures 7–30 µm in length with a pyriform shape, featuring four anterior flagella and one posterior along an undulating , enabling its characteristic . It replicates by binary fission and primarily inhabits the lower genital tract of females ( and ) and the or of males, with humans serving as the only known host. Transmission of T. vaginalis occurs almost exclusively through direct sexual contact, including vaginal intercourse, and can also spread via genital touching or sharing of sex toys, though it does not survive long outside the body. The typically ranges from 5 to 28 days, after which infections may be —particularly in up to 70% of cases—or symptomatic, with women more likely to experience signs such as frothy, foul-smelling , vulvovaginal itching, , and , while men often remain without symptoms but may develop or irritation. Untreated can lead to complications like increased risk of acquisition, adverse pregnancy outcomes (e.g., ), and in women. Epidemiologically, T. vaginalis has a global distribution, with an estimated 156 million new cases annually among individuals aged 15–49, disproportionately affecting regions like and showing higher prevalence among those with multiple sexual partners, other STIs, or in certain demographic groups such as non-Hispanic Black populations in the United States (where rates reach 8.9% in women). The infection is curable with antibiotics such as or , though emerging poses a challenge, and prevention relies on consistent use, partner notification, and routine screening in high-risk populations.

Taxonomy and Phylogeny

Classification

Trichomonas vaginalis belongs to the domain Eukaryota, Metamonada, class Parabasalia, order Trichomonadida, Trichomonadidae, Trichomonas, and species vaginalis. The name Trichomonas derives from words trichos () and monas (unit or single), alluding to the organism's multiple flagella that resemble hairs on a single-celled entity. The specific epithet vaginalis is Latin, referring to its primary habitat in the human vagina. Historically, T. vaginalis was classified within the kingdom based on morphological traits, grouping parabasalids like trichomonads with hypermastigids distinguished by flagella number and nuclear associations. Molecular phylogenetic analyses, particularly using and protein sequences, have refined this placement by confirming the of Parabasalia within Metamonada and reclassifying hypermastigids as polyphyletic, thus integrating T. vaginalis into a more precise eukaryotic framework. Within the genus Trichomonas, T. vaginalis is distinguished from species like T. gallinae, which primarily infects the upper digestive tract of birds and can cause avian trichomonosis. It also differs from the related genus Pentatrichomonas, exemplified by P. hominis, an intestinal parasite in humans and other mammals that inhabits the rather than the urogenital tract.

Evolutionary Relationships

Trichomonas vaginalis belongs to the phylum Parabasalia within the eukaryotic supergroup Metamonada, comprising anaerobic flagellates that lack typical mitochondria and instead possess hydrogenosomes for ATP production under anaerobic conditions. These organelles, derived from mitochondrial ancestors, produce hydrogen gas and are a defining feature of parabasalids, enabling survival in low-oxygen environments like the human urogenital tract. Phylogenetic analyses using 18S rRNA genes and multi-gene datasets consistently place T. vaginalis within the order Trichomonadida of Parabasalia, forming a monophyletic clade with other Trichomonas species. It shows a particularly close relationship to Trichomonas gallinae, a bird pathogen, with evidence from molecular phylogenies indicating that T. vaginalis arose via a host switch from a common bird-infecting ancestor. This evolutionary transition is supported by shared genetic features, such as syntenic regions and conserved genes, highlighting the recent adaptation of trichomonads to mammalian hosts. A 2025 comparative genomics study of seven trichomonad species, including T. vaginalis and T. gallinae, revealed extensive expansions and contractions unique to human-infecting lineages like T. vaginalis. Specifically, T. vaginalis exhibits 140 expanded gene families, particularly in transmembrane , , and virulence-related functions such as adherence and , contributing to a net gain of 116 gene expansions compared to avian relatives. In contrast, 24 multicopy gene families are contracted, reflecting adaptations to the niche following the host switch. These genomic changes underscore among human pathogens within the . While T. vaginalis shares a deeper ancestry with other metamonads, such as in the group Fornicata, their organelles diverge markedly: hydrogenosomes in parabasalids versus mitosomes in fornicate lineages, both representing reductive evolutions from a common mitochondrial progenitor. This distinction highlights the independent trajectories of organelle modification within Metamonada, distinguishing T. vaginalis from typical excavate protists.

Morphology and Life Cycle

Cellular Morphology

Trichomonas vaginalis primarily exists in the stage, which is characteristically pear-shaped (pyriform) and measures 7-30 μm in length by 5-15 μm in width. In laboratory cultures, the maintain a more uniform oval or pear-like morphology, while in the host environment, they often adopt an irregular amoeboid form to facilitate movement and attachment. This variability in shape allows the parasite to adapt to different microenvironments within the urogenital tract. The of T. vaginalis trophozoites is enabled by a distinctive arrangement, consisting of four anterior flagella that project forward from the anterior end and one recurrent flagellum that runs posteriorly along the axostyle, contributing to the undulating membrane—a flap-like structure along the cell's edge. The axostyle itself is a prominent cytoskeletal rod composed of that extends the length of the cell, providing structural support and aiding in attachment to host tissues. Associated with the apparatus is the pelta, a dorsal cap-like structure that reinforces the canal from which the flagella emerge. Internally, the features a single nucleus located anteriorly, which is essential for its genetic material, and multiple hydrogenosomes, double-membrane-bound organelles adapted for anaerobic that are distributed throughout the , often clustered near the undulating membrane and along the axostyle. The surface of the is covered by a plasma membrane embedded with adhesin proteins, such as AP65, AP51, AP33, and AP23, which mediate binding to host epithelial cells. Recent studies have also identified pseudocyst-like spherical forms, approximately 5-10 μm in diameter, that lack visible flagella and may represent a dormant stage linked to persistent infections. For visualization, T. vaginalis trophozoites are commonly observed using wet mount preparations, where their rapid, jerky motility is a key diagnostic feature under light microscopy. Giemsa staining enhances contrast for fixed specimens, highlighting the nucleus, flagella, and axostyle, though it may distort the natural shape compared to live observations.

Reproduction and Transmission

Trichomonas vaginalis exists solely in the trophozoite form throughout its life cycle, lacking a true stage, which facilitates direct transmission between hosts. The parasite replicates within the urogenital tract via longitudinal binary fission, dividing into two identical daughter cells without nuclear membrane breakdown. Following transmission, the typically ranges from 5 to 28 days, after which symptoms may appear if the infection becomes symptomatic. Reproduction in T. vaginalis is primarily asexual through binary fission, but genomic evidence suggests the potential for parasexual processes. The organism possesses orthologs of 27 out of 29 conserved meiotic genes, including eight meiosis-specific genes such as Dmc1 and Msh4/5, indicating a capacity for genetic recombination similar to meiosis in other eukaryotes. This genetic toolkit, combined with observed allelic diversity across strains, supports the hypothesis of occasional sexual or parasexual exchange, though direct observation of meiosis remains elusive. Expression of these genes, particularly under stress conditions like iron depletion, further implies a role in maintaining genetic variation. Transmission occurs predominantly through sexual contact, including vaginal, anal, and oral intercourse, as humans are the sole known . The is shed in vaginal secretions or seminal fluid, infecting new hosts upon direct mucosal contact. Non-sexual routes, such as via contaminated fomites like wet towels or toilet seats, are rare due to the parasite's fragility outside the body. from mother to neonate during birth is possible but uncommon, potentially leading to respiratory or urinary tract infections in infants. Outside the host, T. vaginalis trophozoites are highly sensitive and survive poorly in dry or aerobic conditions, typically dying within minutes to hours. Viability is optimal at 37°C in anaerobic, nutrient-rich environments mimicking the urogenital tract, where they can persist for up to 24 hours in or vaginal fluids but less than 3 hours in or on surfaces. Recent highlights the role of pseudocyst-like structures—non-motile, spherical forms induced by stressors such as or deprivation—in enhancing environmental tolerance and contributing to persistent infections. These pseudocysts, observed in clinical samples and capable of reverting to infectious trophozoites, may explain chronic or recurrent cases resistant to treatment, as demonstrated in animal models where they initiate infection upon reintroduction.

Ecology and Epidemiology

Natural Habitat

Trichomonas vaginalis primarily inhabits the human urogenital tract, colonizing the vagina and cervix in females as well as the urethra, prostate, and semen in males. This protozoan is a human-specific pathogen, with no confirmed non-human reservoirs reported in the literature. T. vaginalis exhibits environmental tolerances suited to the urogenital niche, functioning as an anaerobic or microaerophilic organism with optimal growth at temperatures of 35–40°C and levels ranging from 4.9 to 7.5; it particularly thrives in conditions of disrupted vaginal microbiota, such as those associated with reduced lactobacilli populations. Outside the host, T. vaginalis demonstrates short extracellular survival, persisting for only a few hours in or before viability declines rapidly. Recent has shown that symbiosis with can enhance this extracellular persistence, potentially aiding transmission. In its interaction with the host flora, T. vaginalis targets protective lactobacilli, contributing to dysbiosis by depleting these beneficial and promoting an environment favorable to its own proliferation.

Global Prevalence and Risk Factors

Trichomonas vaginalis infection imposes a significant burden, with an estimated 156 million new cases annually among individuals aged 15–49 years (as of 2020), primarily affecting women. A 2025 systematic review and reported a pooled of 8% (95% CI: 7%–10%), though rates vary widely by and region, underscoring the parasite's status as the most common non-viral ; earlier WHO estimates indicated 5.3% among women (2016 data). In the United States, approximately 2.6 million people are infected (as of 2024), representing a notable challenge despite underreporting due to cases. Regional variations in prevalence highlight disparities in transmission dynamics and healthcare access. bears the highest burden, with rates reaching up to 31.9% in certain Nigerian populations attending medical centers. In contrast, prevalence in has shown a decreasing trend, dropping to 3.41% overall in from 2019 to 2023, attributed to improved screening and awareness efforts. Demographic factors significantly influence risk, with women experiencing higher rates than men; for instance, U.S. among women is about 2.1%, particularly elevated among non-Hispanic Black women at 9.6%. Middle-aged groups (e.g., 35–54 years) often show peak vulnerability in various studies, as do smokers and those with histories. Low-income groups face compounded risks due to limited preventive resources. Socioeconomic determinants further exacerbate transmission, including having multiple sexual partners, inconsistent condom use, and barriers to screening access that perpetuate disparities in underserved communities. These factors often intersect with behavioral risks like substance use, amplifying infection rates in vulnerable populations. Recent 2025 analyses, including meta-regressions, indicate stable global trends overall but rising incidence in high-risk groups such as attendees at sexually transmitted infection clinics, where prevalence can exceed 12.9%, signaling the need for targeted interventions.

Pathogenesis and Virulence

Mechanisms of Infection

Trichomonas vaginalis initiates infection through the adhesion of its trophozoite stage to the urogenital epithelium, primarily via the axostyle and anterior flagella, which facilitate close contact with host cells. This attachment is mediated by surface molecules such as adhesins and lipophosphoglycan (LPG), enabling the parasite to bind to host receptors like galectin-1 on vaginal epithelial cells. Once adhered, T. vaginalis induces cytotoxicity through contact-dependent mechanisms, including the release of cysteine proteases and pore-forming proteins that cause host cell lysis, necrosis, and apoptosis, thereby damaging the epithelial barrier. This process is enhanced by proteins like TvROM1, which increase lytic activity up to fourfold. To evade the host , T. vaginalis secretes extracellular vesicles, such as exosomes, that deliver cargo to host cells, modulating responses by increasing IL-10 and decreasing pro-inflammatory cytokines such as IL-6 and IL-17, while exosomes can reduce IL-8 production. Additionally, the parasite alters the vaginal microenvironment by increasing pH and inhibiting growth, which promotes and favors anaerobic bacterial overgrowth, further impairing innate defenses. proteases also degrade immunoglobulins like IgA and IgG, while of leukocytes by trophozoites tempers inflammatory responses. Tissue invasion occurs as trophozoites undergo amoeboid transformation, adopting a pseudopod-extending morphology that allows deeper penetration into the mucosal layers. This invasion triggers through the production of (ROS) and activation of the in host cells, leading to localized tissue damage and release. Chronic is maintained by the formation of , non-motile spherical structures induced by environmental stresses like iron depletion or low , which enable survival outside the host and reversion to infectious trophozoites under favorable conditions. Symbiotic interactions with mycoplasmas, particularly , contribute to persistence through biofilm-like formations that enhance resistance to antimicrobials and immune clearance, with co- rates reaching up to 92% in some populations. Recent metabolomic analyses confirm that pseudocyst formation involves synthesis and breakdown, supporting long-term viability. The host mounts an initial response by recruiting neutrophils via IL-8 production, which attempt to eliminate the parasite through and oxidative bursts. However, clearance remains ineffective without treatment, as T. vaginalis counters with mechanisms like DNase II secretion to degrade and clumping behaviors that resist . This results in persistent and suboptimal resolution.

Virulence Factors

Trichomonas vaginalis employs several key factors that facilitate its adherence to host tissues, evasion of immune responses, and induction of cellular . Among these, adhesins such as AP65 and AP23 play critical roles in mediating parasite binding to vaginal epithelial cells. AP65, a 65-kDa surface protein, is a prominent adhesin that promotes stable attachment to host cells, as demonstrated by its localization on the parasite surface and reduction in adherence upon . Similarly, AP23, a 23-kDa protein, contributes to cytoadherence, particularly under iron-replete conditions that mimic the host environment, enhancing parasite colonization. studies have confirmed these roles; for instance, antibodies targeting related adhesins like AP33 significantly inhibit binding to epithelial monolayers, underscoring the functional importance of this protein family in infection initiation. Cysteine proteinases represent another major class of virulence factors, with over 200 genes encoding these enzymes in the T. vaginalis , far exceeding numbers in other eukaryotes and enabling diverse pathogenic functions. These proteases, including the iron-inducible TVCP4, degrade host immunoglobulins such as IgA, IgG, and IgM, thereby impairing and allowing parasite survival in the genital tract. TVCP4 specifically contributes to and by cleaving host proteins, while the broader family targets components like and , facilitating tissue invasion and nutrient acquisition. This proteolytic arsenal is upregulated during host cell contact, amplifying damage to epithelial barriers. with Trichomonas vaginalis (TVV) further enhances expression of these proteases, increasing and inflammatory responses (as of 2025). Surface lipophosphoglycans (LPGs) further enhance by modulating host-parasite interactions. These glycoconjugates coat the parasite surface and promote immune evasion by binding to host galectins, such as galectin-1 and -3 on cervical cells, which inhibits recruitment and . LPG mutants exhibit reduced adherence and toward ectocervical cells, highlighting their role in direct host cell damage through contact-dependent mechanisms that trigger dysregulation. This dual function in adhesion and sustains chronic infection. Hydrogenosomes, the anaerobic equivalents of mitochondria in T. vaginalis, contribute to virulence by generating (ROS) that inflict oxidative damage on host cells. During infection, hydrogenosomal metabolism shifts to produce ROS, which induce in epithelial cells via DNA damage and stress pathways, independent of classical . This ROS-mediated enhances parasite survival by clearing local host defenses. Recent comparative genomic analyses in 2025 have revealed expanded families in T. vaginalis relative to other trichomonads, including avian . These expansions involve multicopy families (up to 16 major ones) associated with cell surface proteins and host interaction loci, driving for human adaptation and spillover potential from bird reservoirs. Such genomic features underlie the parasite's heightened pathogenic capacity compared to non-pathogenic relatives like Trichomonas tenax.

Clinical Features

Historical Recognition

Trichomonas vaginalis was first described in 1836 by French physician and microscopist Alfred François Donné, who observed motile protozoans in purulent from patients and named the "le trichomonas vaginalis." Donné's identification marked the initial microscopic recognition of the parasite, though at the time it was not immediately linked to and was often viewed as a harmless commensal in the . Early observations sometimes led to misconceptions, with the flagellated protozoan being confused with cells, forms, or bacterial elements due to limitations in and techniques available in the . Clinical recognition of T. vaginalis as a emerged gradually in the late 19th and early 20th centuries. Although sporadic reports suggested an association with in the 1880s, it was not until 1916 that German gynecologist Otto Hohne firmly established the link by describing as a distinct clinical entity characterized by purulent colpitis, coining the term "trichomoniasis" and emphasizing the parasite's etiological role in vaginal inflammation. By the mid-20th century, particularly post-1950s, the understanding shifted dramatically toward viewing as a (STI), supported by epidemiological evidence of its transmission patterns and the development of effective treatments like in 1959, which confirmed its pathogenic potential. Key milestones in the historical understanding of T. vaginalis include the successful axenic cultivation of the parasite in the 1940s, achieved by researchers such as R.R. Trussell in 1940, which allowed for controlled studies on its and pathogenicity without bacterial contamination. In the , large-scale studies like the Vaginal Infections and Prematurity Study demonstrated the parasite's association with adverse pregnancy outcomes, including and , elevating its significance. The first draft sequence, published in 2007, provided insights into its complex biology and further solidified its role as a major STI pathogen. The recognizes as a curable STI as part of global control efforts, given its widespread prevalence and need for integrated management.

Signs and Symptoms

Trichomoniasis caused by Trichomonas vaginalis is often , with approximately 85% of infected women and 77% of infected men showing no symptoms. The typically ranges from 5 to 28 days following exposure. In women, symptomatic cases commonly present with a frothy, yellow-green that may have a foul , accompanied by , , and vulvar itching or irritation. On , a characteristic "" may be observed in some cases, featuring punctate hemorrhages on an erythematous . Men with symptomatic may experience urethral discharge, pruritus, or burning during micturition; complications such as or occur rarely. Women are more likely to develop symptoms than men, as the vaginal environment favors parasite proliferation, whereas men frequently serve as reservoirs facilitating transmission. Atypical presentations of are rare in postmenopausal women or prepubertal children, though symptoms in these groups can resemble those in reproductive-age adults when infection occurs.

Complications

Untreated Trichomonas vaginalis infection in pregnant women is associated with adverse reproductive outcomes, including preterm delivery, , and (PROM), with meta-analyses indicating a 1.3- to 2-fold increased risk for these complications. Specifically, the odds ratio for preterm delivery is approximately 1.27 (95% CI: 1.08–1.50), for PROM 1.87 (95% CI: 1.53–2.29), and for 2.12 (95% CI: 1.15–3.91). These risks arise from the parasite's induction of inflammation and disruption of cervical barriers, contributing to early labor and fetal growth restriction. T. vaginalis infection heightens susceptibility to acquisition and transmission through epithelial cell damage and genital inflammation, elevating the risk by 1.5- to 3-fold, with consistent evidence from high-prevalence regions such as and African-American communities. As of 2024, the reaffirms this association, particularly in areas with overlapping epidemics, where the parasite's cytotoxic effects facilitate viral entry. Beyond these, chronic T. vaginalis infection is linked to (PID), , and , with cohort studies showing an approximate 2-fold increased for cervical neoplasia. The association with PID stems from ascending infection causing and , particularly in immunocompromised individuals, while results from tubal scarring and impaired ovum transport in prolonged cases. For cervical cancer, the risk is amplified by co-infection with high-risk HPV, promoting through chronic inflammation. In males, T. vaginalis can lead to chronic , characterized by persistent urethral and glandular damage, which contributes to by reducing and viability. Excretory-secretory products from the parasite adhere to spermatozoa, inducing and functional impairment in a dose-dependent manner. Research from 2024 highlights increased adverse outcomes in screened populations, with studies in diverse cohorts showing higher rates of preterm labor and among T. vaginalis-positive pregnant women identified through routine testing. These findings underscore the value of early detection in mitigating risks, though persistent infections remain a challenge in resource-limited settings.

Diagnosis and Management

Diagnostic Techniques

Diagnosis of Trichomonas vaginalis infection typically involves a combination of microscopic examination, culture, and molecular methods, with the choice depending on clinical setting, specimen type, and resource availability. amplification tests (NAATs) are now recommended as the most sensitive approach by health authorities, particularly for detecting asymptomatic or low-burden infections, while traditional wet-mount remains a rapid, low-cost option in resource-limited environments. Wet-mount microscopy involves preparing a saline suspension of vaginal secretions (in women) or urethral swabs/urine (in men) and examining it under a for motile trophozoites, which exhibit characteristic jerky movements and flagella. This method has a sensitivity of 44%–68% in women, dropping to as low as 20%–30% in men due to lower parasite loads, and requires immediate as motility declines rapidly after sample collection. Its specificity approaches 100%, but it is operator-dependent and misses many cases, especially in asymptomatic individuals. Culture techniques, such as those using Diamond's modified medium or commercial systems like InPouch TV, allow for the growth of viable parasites and serve as a historical gold standard, particularly for assessing drug susceptibility. These methods achieve sensitivities of 75%–95% and specificities near 100%, outperforming wet mounts, but require 3–7 days for results and specialized anaerobic incubation at 35–37°C; vaginal secretions or urethral swabs yield the best results, with multiple specimens improving detection rates. Molecular tests, including NAATs like polymerase chain reaction (PCR), transcription-mediated amplification (TMA), and strand displacement amplification, detect T. vaginalis DNA or RNA in vaginal swabs, endocervical swabs, urine, or even Pap specimens, with sensitivities exceeding 95% and specificities of 95%–100%. FDA-cleared assays such as the Aptima TV assay (95%–100% sensitivity), BD ProbeTec TV Qx (98% sensitivity), and Cepheid GeneXpert TV (99%–100% sensitivity) are widely used; the latter provides results in under 1 hour and is cleared for both sexes. Recent multiplex NAATs, including those from 2024, enable simultaneous detection of co-infections like chlamydia and gonorrhea, enhancing efficiency in STI screening. Rapid antigen detection tests, such as the OSOM Trichomonas Rapid Test, identify parasite antigens in vaginal or urine samples with sensitivities of 82%–95% in women (lower at ~38% in men) and specificities of 97%–100%, offering point-of-care results in 10–15 minutes but lacking the sensitivity of NAATs for low-prevalence settings. Pap smears incidentally detect T. vaginalis in 50%–60% of cases but have poor sensitivity for infections and are not recommended for primary , as confirmatory NAAT is required. Diagnostic challenges include lower parasite burdens in men, necessitating optimized specimen collection like first-void urine or urethral swabs, and the need for same-day processing in to preserve ; NAATs mitigate these issues but require laboratory infrastructure. In high-prevalence populations, combining methods (e.g., wet mount followed by NAAT on negatives) maximizes yield without excessive cost.

Treatment Options

The primary treatment for Trichomonas vaginalis infection is with antibiotics, which are highly effective against the parasite. The Centers for Disease Control and Prevention (CDC) recommends as the first-line therapy, administered either as a single 2 g oral dose or 500 mg orally twice daily for 7 days, achieving cure rates of approximately 90% in clinical settings. serves as an effective alternative, typically given as a single 2 g oral dose, with efficacy comparable to metronidazole based on systematic reviews showing similar microbiological cure rates exceeding 90%. Secnidazole, another nitroimidazole, was approved by the U.S. in 2021 for treating in adults and later expanded to adolescents aged 12 years and older; it is administered as a single 2 g oral dose of granules, offering improved compliance due to its one-time regimen while demonstrating microbiological cure rates around 92%. Metronidazole resistance in T. vaginalis affects 4%–10% of cases globally, with 2025 studies highlighting increasing in certain regions and urging . For resistant infections, management involves higher-dose regimens (e.g., 500 mg three times daily for 7 days), switching to , or with metronidazole plus tinidazole, which can achieve cure rates over 90% in refractory cases. Treatment of sexual partners is crucial to prevent reinfection, as up to 20% of cases recur due to untreated contacts; the CDC advises simultaneous treatment of all partners, including individuals, using the same regimens as for the index patient. In pregnant individuals, is recommended for symptomatic regardless of trimester, with a preferred single 2 g oral dose to minimize risks, though earlier guidelines suggested delaying until after the first trimester due to limited data on fetal effects. Emerging in 2025 has demonstrated activity of and its metabolite tizoxanide against both metronidazole-susceptible and resistant T. vaginalis isolates, suggesting potential as an alternative, though clinical trials are needed.

Prevention Strategies

Prevention of Trichomonas vaginalis infection primarily relies on behavioral strategies to reduce sexual transmission. Consistent and correct use of external or internal condoms during vaginal is the most , reducing the odds of acquiring by approximately 59% among sexually active individuals. Limiting the number of sexual partners further decreases risk, as multiple partners increase exposure opportunities. Partner notification and concurrent management of sexual partners are essential to prevent reinfection, with expedited partner therapy recommended where legally available to facilitate prompt intervention without requiring partner evaluation. Screening plays a key role in high-risk populations to detect and mitigate infections. The Centers for Disease Control and Prevention (CDC) recommends diagnostic testing for women presenting with and considers annual screening for women in high-prevalence settings, such as (STI) clinics, correctional facilities, or those with risk factors including multiple partners, history of STIs, substance use, or . Routine annual screening is advised for women living with due to elevated prevalence and potential for adverse outcomes. For pregnant women, screening is prioritized if symptomatic or high-risk, though routine screening for all pregnant individuals lacks sufficient evidence of benefit. Public health initiatives emphasize education on STI risks and integration of T. vaginalis control into broader programs, particularly those addressing , given the parasite's role in increasing HIV acquisition risk by up to 1.5-3 times. The (WHO) promotes accessible diagnostics, partner notification services, and enhanced case management as part of its global strategy to reduce new trichomoniasis cases by 50% by 2030. Community education campaigns focus on promotion and practices to empower individuals in preventing transmission. No against T. vaginalis is currently available, though preclinical in 2025 has explored multi-epitope and protein-based candidates targeting adhesins like AP65 and α-actinin to elicit immune responses. Challenges in prevention include the high rate of infections—over 50% in women and most men—which facilitates undetected spread, and disparities in access to screening and care, with one-third of new cases occurring in the WHO African Region and elevated prevalence among populations in the United States.

Molecular Biology

Genome Structure

The genome of Trichomonas vaginalis spans approximately 180 megabases (Mb) and is distributed across six chromosomes, making it one of the largest among protozoan parasites. Recent annotations predict approximately 25,000–38,000 protein-coding genes, with a significant portion dedicated to functions such as adhesion and immune evasion. Roughly 65% of the genome comprises repetitive DNA, including transposons and virus-like elements that contribute to its structural complexity and plasticity. The initial draft genome sequence was completed in 2007 by the Broad Institute using a combination of whole-genome and bacterial artificial chromosome libraries from strain G3, providing the foundational reference despite challenges from repetitive regions. More recently, a high-quality chromosome-level assembly of strain TV-THS1 was generated in 2024 using long-read PacBio sequencing and , improving contiguity and enabling precise annotation of chromosomal structures. Key genomic features include the absence of introns in the majority of protein-coding genes, with only about 63 confirmed active spliceosomal introns identified across the proteome, reflecting a streamlined splicing machinery compared to other eukaryotes. The genome exhibits extensive expansions in gene families encoding surface proteins, such as adhesins and immunogens, which are crucial for host interaction. Recent studies have also revealed adenine DNA methylation patterns and 3D genome organization that influence gene expression and chromatin looping in the parasite. Resources like the TrichDB database facilitate access to these sequences, annotations, and comparative tools for researchers. Certain strains of T. vaginalis harbor endosymbionts that influence -related studies, including , a bacterium that resides intracellularly in up to 90% of isolates and can complicate sequencing assemblies due to co-culture. Additionally, the double-stranded Trichomonas vaginalis virus (TVV) infects some strains, existing as an extrachromosomal element that modulates parasite without integrating into the host . Comparative genomic analyses highlight T. vaginalis as having undergone substantial gene duplications relative to other trichomonads like Trichomonas tenax, resulting in the largest expansion of multicopy gene families and contributing to its adaptive repertoire in the human urogenital tract.

Metabolism

Trichomonas vaginalis is an obligate anaerobe that derives its energy primarily through fermentative metabolism, lacking conventional mitochondria and the tricarboxylic acid (Krebs) cycle. Instead, it possesses hydrogenosomes, double-membrane-bound organelles that function as sites of anaerobic ATP production and hydrogen gas evolution. Glycolysis in the cytosol converts glucose to pyruvate, yielding a net of two ATP molecules per glucose via substrate-level phosphorylation. Pyruvate is then transported into the hydrogenosome, where it is decarboxylated by pyruvate:ferredoxin oxidoreductase (PFOR) to form acetyl-CoA, carbon dioxide, and reduced ferredoxin. The reduced ferredoxin donates electrons to [Fe]-hydrogenase, generating molecular hydrogen (H₂) to maintain redox balance. Acetyl-CoA is further metabolized through the acetate:succinate CoA-transferase (ASCT)/succinyl-CoA synthetase (SCS) cycle, producing acetate and an additional ATP molecule while recycling succinate. An alternative pathway involves the conversion of phosphoenolpyruvate to malate in the cytosol, followed by its oxidation in the hydrogenosome to pyruvate via malate dehydrogenase and NADH:ferredoxin oxidoreductase, also producing H₂. The parasite ferments glucose to a variety of end products, including lactate (via cytosolic ), glycerol, ethanol, succinate, , H₂, and CO₂. Nutrient uptake occurs primarily through and mechanisms for glucose and other carbohydrates, allowing adaptation to varying host environments. supplements energy needs, particularly under glucose limitation; for instance, is degraded by methionine γ-lyase to , , and 2-ketobutyrate, while is converted to 2-hydroxyisocaproic acid. These catabolic processes support both energy generation and of essential metabolites, such as S-methylcysteine from and . Nitroimidazoles, such as metronidazole, target hydrogenosomal metabolism by exploiting the parasite's electron transport system; these prodrugs are reduced by PFOR and ferredoxin to cytotoxic nitroso radicals that damage DNA and proteins. This mechanism underscores the hydrogenosome's vulnerability as a therapeutic target, with activation occurring specifically under anaerobic conditions. T. vaginalis exhibits microaerotolerance, tolerating low oxygen levels through thioredoxin and flavodiiron protein systems that scavenge reactive oxygen species, preventing oxidative damage to hydrogenosomal enzymes. Additionally, the parasite maintains redox homeostasis via associations with symbiotic bacteria, such as hydrogen-oxidizing Mycoplasma hominis, which consume excess H₂ and mitigate end-product inhibition of metabolism.

Genetics and Evolution

Genetic Diversity

Trichomonas vaginalis exhibits considerable genetic variation among clinical isolates, primarily assessed through (MLST) schemes that target genes to identify sequence types (STs). A next-generation MLST analysis of 178 isolates from and identified 71 polymorphic nucleotide sites, yielding 36 distinct alleles and 48 STs, 24 of which were novel, highlighting substantial intraspecific diversity. This approach has revealed clustering into eight groups, with evidence of ongoing genetic exchange despite an overall clonal population structure characterized by . The parasite displays a unique biphasic structure consisting of two major lineages: Type 1, associated with higher pathogenicity and greater rates by the Trichomonas vaginalis (TVV), and Type 2, which exhibits commensal-like traits and increased resistance. Although recombination events occur, particularly in single-copy genes, the remains predominantly clonal, with Type 1 showing linkage equilibrium suggestive of more frequent genetic exchange, while Type 2 demonstrates significant disequilibrium. This structure is globally distributed in near-equal proportions, but regional biases exist, such as Type 1 dominance in . Geographic patterns of genetic diversity vary, with higher allelic frequencies and polymorphism observed in African populations compared to , where fewer STs are typically reported among isolates. In the , studies from regions like and indicate limited variation, with genotyping revealing predominantly Type 1 isolates and limited in local cohorts. Contributing factors include endosymbiotic infections; TVV presence in Type 1 strains has been linked to altered potentially enhancing resistance in some isolates, while co-infection with Mycoplasma species, such as , introduces additional genetic variability by modulating parasite pathobiology and . These strain-specific differences underscore implications for clinical outcomes, as Type 1 lineages correlate with increased factors like enhanced adherence and , influencing disease severity. Ongoing surveillance of is essential to track emerging resistant strains and inform targeted interventions.

Evolutionary History

Trichomonas vaginalis is believed to have evolved from a free-living within the supergroup, transitioning to a parasitic in the lineage of parabasalids. Phylogenetic analyses indicate that the common of Trichomonadea, the class including T. vaginalis, was likely free-living, with subsequent leading to in . This shift involved specialization to anaerobic environments, such as the vertebrate gut, before further adaptation to the urogenital tract. Comparative studies of related taxa, like free-living Pseudotrichomonas keilini, support that arose after divergence from free-living relatives, marking a key evolutionary step in the group's history. The of T. vaginalis has undergone significant , with initial sequencing suggesting extensive events that expanded its repertoire to over 60,000 genes, though recent chromosome-level assemblies (as of 2025) estimate 25,000–45,000 protein-coding genes, reflecting one of the larger genomes. These duplications, including potential whole-genome events, have contributed to metabolic versatility and to host environments. Notably, T. vaginalis lacks typical mitochondria, instead possessing hydrogenosomes—modified organelles derived from ancestral mitochondria through reductive . This involved the complete loss of the mitochondrial and relocation of genes to the nucleus, enabling anaerobic energy production via release, a trait advantageous in the oxygen-poor urogenital niche. Such organellar remodeling highlights with other anaerobic eukaryotes. Reproduction in T. vaginalis is predominantly asexual via binary fission, but genomic evidence points to an ancient capability for sexual processes. The presence of orthologs for 27 out of 29 conserved meiotic genes, including meiosis-specific proteins, suggests that sexual recombination may have occurred in its evolutionary past or persists in undetected forms, potentially as parasexuality. This genetic toolkit implies a shift toward asexual dominance, possibly to facilitate rapid proliferation in hosts, while retaining elements for occasional genetic exchange. Adaptation to mammalian hosts represents a pivotal event in T. vaginalis , involving a host switch from avian ancestors like Trichomonas gallinae. Phylogenetic evidence traces this jump to a bird-to-mammal transition, occurring independently at least twice, with T. vaginalis specializing in s. A 2025 comparative genomics study across trichomonad identified gene expansions in adhesion, immune evasion, and —particularly with mycoplasmas—that facilitated this spillover, enabling persistence in the human urogenital tract. These adaptations underscore the parasite's opportunistic from avian oral cavities to human mucosa. Looking ahead, the evolutionary trajectory of T. vaginalis raises concerns for , as its high and predominantly may promote emerging through mechanisms like and selection. Studies on metronidazole-resistant strains reveal shared genetic changes across isolates, indicating conserved adaptive pathways that could accelerate resistance evolution in response to treatment pressures. This potential, driven by population bottlenecks and host-switching history, highlights the need for vigilant genomic surveillance.

References

  1. https://www.cdc.gov/dpdx/trichomoniasis/index.html
  2. https://www.who.int/news-room/fact-sheets/detail/trichomoniasis
  3. https://www.ncbi.nlm.nih.gov/books/NBK534826/
  4. https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=info&id=5722
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC9562425/
  6. https://onlinelibrary.wiley.com/doi/10.1111/jeu.13035
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7106558/
  8. https://academic.oup.com/bioscience/article/55/8/657/264621
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4437511/
  10. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0020774
  11. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1242275/full
  12. https://www.nature.com/articles/s41467-025-61483-w
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC1182405/
  14. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000243
  15. https://journals.lww.com/ijst/fulltext/2008/29010/an_update_on_trichomonas_vaginalis.2.aspx
  16. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1055-0
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2488364/
  18. https://pubmed.ncbi.nlm.nih.gov/18663385/
  19. https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm
  20. https://emedicine.medscape.com/article/230617-overview
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC10844888/
  22. https://doi.org/10.1016/j.pt.2023.09.009
  23. https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/trichomonas-vaginalis.html
  24. https://www.infectiousdiseaseadvisor.com/home/decision-support-in-medicine/infectious-diseases/trichomonas/
  25. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540562/all/Trichomonas_vaginalis
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC106834/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC1594771/
  28. https://turkiyeparazitolderg.org/articles/survival-of-trichomonas-vaginalis-in-various-environments-and-at-different-temperatures/22580
  29. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011563
  30. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2020.00179/full
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC12386857/
  32. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1530227/full
  33. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-025-10815-8
  34. https://www.medrxiv.org/content/10.1101/2025.08.12.25333487v1
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC6445371/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC11132421/
  37. https://pubmed.ncbi.nlm.nih.gov/28345149/
  38. https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-018-2796-4
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC5354568/
  40. https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-7-116
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2562645/
  42. https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2958.2003.03366.x
  43. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.01433/full
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC4209856/
  45. https://journals.asm.org/doi/pdf/10.1128/iai.63.9.3388-3395.1995
  46. https://onlinelibrary.wiley.com/doi/10.1155/2015/946787
  47. https://www.mdpi.com/2076-0817/13/2/119
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC12298157/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC4705417/
  50. https://journals.asm.org/doi/10.1128/ec.4.11.1951-1958.2005
  51. https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-021-05098-2
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5748870/
  53. https://www.biorxiv.org/content/10.1101/2024.12.22.629724v1
  54. https://pubmed.ncbi.nlm.nih.gov/19401511/
  55. https://www.news-medical.net/health/What-Causes-Trichomoniasis.aspx
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC1045069/
  57. https://pubmed.ncbi.nlm.nih.gov/15054166/
  58. https://www.ajtmh.org/view/journals/tpmd/2/2/article-p267.xml
  59. https://pubmed.ncbi.nlm.nih.gov/9243743/
  60. https://pubmed.ncbi.nlm.nih.gov/17218520/
  61. https://academic.oup.com/cid/article/74/Supplement_2/S152/6567967
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC10713349/
  63. https://emedicine.medscape.com/article/230617-clinical
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC9704755/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC3892600/
  66. https://pubmed.ncbi.nlm.nih.gov/8002180/
  67. https://pubmed.ncbi.nlm.nih.gov/11797180/
  68. https://pubmed.ncbi.nlm.nih.gov/8520717/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC9608160/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC4650456/
  71. https://journals.lww.com/jocs/fulltext/2024/21040/prevalence_of_trichomonas_vaginalis_infection_and.5.aspx
  72. https://www.ajog.org/article/S0002-9378%2825%2900498-3/fulltext
  73. https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-025-07196-1
  74. https://emedicine.medscape.com/article/230617-workup
  75. https://www.aphl.org/aboutAPHL/publications/Documents/ID_2013August_Advances-in-Laboratory-Detection-of-Trichomonas-vaginalis.pdf
  76. https://pubmed.ncbi.nlm.nih.gov/9399542/
  77. https://journals.asm.org/doi/10.1128/jcm.01291-11
  78. https://pubmed.ncbi.nlm.nih.gov/39842023/
  79. https://.ncbi.nlm.nih.gov/12592239/
  80. https://journals.asm.org/doi/10.1128/jcm.01656-08
  81. https://emedicine.medscape.com/article/230617-treatment
  82. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209363s014s016lbl.pdf
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC9844242/
  84. https://pubmed.ncbi.nlm.nih.gov/41185508/
  85. https://www.cdc.gov/trichomoniasis/about/index.html
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC7044808/
  87. https://journals.asm.org/doi/10.1128/spectrum.02717-24
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC3502658/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC9006969/
  90. https://pubmed.ncbi.nlm.nih.gov/40779085/
  91. https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-024-06248-y
  92. https://www.sciencedirect.com/science/article/pii/S2949924024000077
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC2080659/
  94. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013282
  95. https://pubmed.ncbi.nlm.nih.gov/17962075/
  96. https://www.pnas.org/doi/10.1073/pnas.1917286117
  97. https://www.hsls.pitt.edu/obrc/index.php?page=URL1240581170
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC9239101/
  99. https://www.sciencedirect.com/science/article/pii/S0923250817300657
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC7677174/
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC5739422/
  102. https://doi.org/10.1371/journal.pone.0189072
  103. https://doi.org/10.1017/S0031182020001237
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC7226223/
  105. https://pubmed.ncbi.nlm.nih.gov/32278146/
  106. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001573
  107. https://www.researchgate.net/figure/Allelic-frequency-and-diversity-in-different-continents-A-Europe-B-Africa-C-America_fig1_356364759
  108. https://www.researchgate.net/publication/338287262_Genotyping_of_Trichomonas_vaginalis_isolates_from_Egypt
  109. https://www.mdpi.com/1999-4915/17/7/898
  110. https://journals.asm.org/doi/10.1128/mbio.00918-22
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC3749517/
  112. https://www.biorxiv.org/content/10.1101/2024.09.26.614816v1.full-text
  113. https://www.nature.com/articles/s41597-025-06182-3
  114. https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2013.03.001
  115. https://academic.oup.com/gbe/article/4/10/1017/554045
  116. https://academic.oup.com/mbe/article/37/2/524/5606724
  117. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002879
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC5843343/
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC5522705/
Add your contribution
Related Hubs
User Avatar
No comments yet.